Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment is a phase 2 interventional study registered as NCT06841055 by BioNTech SE, with 60 participants planned, started 2025-03-03 and due to reach its primary completion in 2028-10. Interventions recorded: Pumitamig, Docetaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.